sendegobresib (CFT8634)

Further, the advancement of CFT8634 as a monotherapy was inhibited by the emergence of cardiac toxicities. Nevertheless, this first study of an orally bioavailable BRD9 degrader recapitulates preclinical pharmacokinetic and pharmacodynamic observations in a clinical trial setting.

P1, N=49, Terminated, C4 Therapeutics, Inc. | Phase classification: P1/2 --> P1

P1/2, N=50, Terminated, C4 Therapeutics, Inc. | Active, not recruiting --> Terminated; High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated synovial sarcoma and SMARCB1-null solid tumor patients treated with CFT8634 as a single agent.

P1/2, N=50, Active, not recruiting, C4 Therapeutics, Inc.

Additionally, in vitro synergy in MM proliferation assays was observed when a tool BRD9 degrader was combined with the standard of care (SoC) agents, dexamethasone or pomalidomide. In conclusion, we demonstrate in vitro and in vivo activity in an expanded set of MM models using the clinical oral BRD9 degrader CFT8634 as a single agent and show in vivo synergy between CFT8634 and pomalidomide at clinically relevant doses. Our findings suggest that combining CFT8634 with pomalidomide may be a viable therapeutic strategy in treating MM patients.

P1/2, N=50, Active, not recruiting, C4 Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=110 --> 50

Preliminary findings from CFT8634-1101 indicate that CFT8634 demonstrated favorable tolerability and safety at early dose levels. Updated data to be presented at the conference.

Approximately 110 patients at approximately 10 US sites will be enrolled. This trial is registered with clinicaltrials.gov as NCT05355753, and is open to enrollment.

P1/2, N=110, Recruiting, C4 Therapeutics, Inc.